Annual Congress Vienna 2009

---

---

The new ERS/ATS/IASLC classification of lung adenocarcinoma: practice update

Symposium
Chairs: K. M. Kerr (Foresterhill, Aberdeen, United Kingdom), P. Van Schil (Edegem (Antwerp), Belgium)
Aims: To present a new multidisciplinary subclassification of lung adenocarcinoma developed by an international panel of lung cancer experts sponsored by ERS/ATS and IASLC. After attending this symposium the audience will understand how this classification will:
a) Resolve the ongoing discrepancy in the pathologic vs clinical use of the term bronchoalveolar cell carcinoma - which currently determines 100% vs 5-20% 5-year survival, respectively;
b) Recommend an international standard for histological subclassification of lung adenocarcinomas;
c) Define clinical/histological/radiological/molecular subtypes of lung adenocarcinoma and define clinical, radiological, pathologic and molecular terminology and criteria.

History of lung adenocarcinoma classification. Overview and pathology of new ERS/ATS/IASLC proposal W. Travis (New York, Nj, United States of America)
The role of radiology in lung adenocarcinoma classification K. Garg (Denver, Colorado, United States of America)
Implications of new lung adenocarcinoma classification for oncologists J. Vansteenkiste (Leuven, Belgium)